Bernice L. Robinson-Bennett
Expertise in
18
conditions

Dr. Bernice L. Robinson-Bennett

Oncology | Obstetrics and Gynecology
420 S 5th Avenue, Bldg N, 
West Reading, PA 
Expertise in
18
conditions
420 S 5th Avenue, Bldg N, 
West Reading, PA 

Overview

Bernice Robinson-Bennett is an Oncologist and an Obstetrics and Gynecologist practicing medicine in West Reading, Pennsylvania.

Dr. Robinson-Bennett is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Cervical Cancer, and Bladder Reconstruction.

Dr. Robinson-Bennett is board certified in American Board Of Obstetrics And Gynecology. She is actively involved in clinical research, co-authoring 3 peer reviewed articles and participating in 7 clinical trials.

Specialties

Oncology
Obstetrics and Gynecology

Licenses

Obstetrics & Gynecology in TX
  in  

Board Certifications

American Board Of Obstetrics And Gynecology

Fellowships

University of Texas Medical Health Science Center, Gynecologic Oncology

Hospital Affiliations

 
Pottstown Hospital
Penn State Health St. Joseph
Reading Hospital
Phoenixville Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Tower Health Medical Group Gynecologic Oncology - West Reading
420 S 5th Avenue, Bldg N, West Reading, PA 19611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 30, 2025
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

3 Total Publications

Surgically Enucleated Gastrointestinal Tumor of the Rectovaginal Septum.
Surgically Enucleated Gastrointestinal Tumor of the Rectovaginal Septum.
Journal: Cureus
Published: September 10, 2019
Similar Doctors
Expertise in
19
conditions
Dr. Mark S. Shahin
Oncology | Obstetrics and Gynecology
Expertise in
19
conditions
Dr. Mark S. Shahin
Oncology | Obstetrics and Gynecology
Referral may be required
Before you request

Alliance Cancer Specialists

1203 Langhorne-Newtown Road, Suite 135, 
Langhorne, PA 
 (54.8 miles away)
215-750-5050
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Shahin is an Oncologist and an Obstetrics and Gynecologist practicing medicine in Langhorne, Pennsylvania. Dr. Shahin is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Hysterectomy, and Lymphadenectomy. Dr. Shahin is board certified in Gynecologic Oncology, American Board Of Obstetrics And Gynecology and American Board Of Obstetrics And Gynecology. Dr. Shahin is currently accepting new patients.

Expertise in
24
conditions
Expertise in
24
conditions
Referral may be required

University Of Pennsylvania

3400 Civic Center Blvd, 
Philadelphia, PA 
 (47.9 miles away)
215-615-5858
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jakub Svoboda is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Svoboda is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Classical Hodgkin Lymphoma, B-Cell Lymphoma, and Bone Marrow Aspiration.

Expertise in
14
conditions
Expertise in
14
conditions
Referral may be required
Before you request

Penn Mesothelioma And Pleural Program

51 N. 39th Street, Pavilion For Advanced Care, First Floor, 
Philadelphia, PA 
 (47.3 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Corey Langer is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Langer is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Mesothelioma, and Tissue Biopsy. Dr. Langer is board certified in Hematology, 1986, Medical Oncology, 1987, and Internal Medicine, 1984. Dr. Langer is currently accepting new patients.

Frequently Asked Questions about Dr. Bernice L. Robinson-Bennett

How do I make an appointment with Dr. Bernice L. Robinson-Bennett?

You can book an appointment with Dr. Bernice L. Robinson-Bennett by calling their office at 484-628-8905. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Bernice L. Robinson-Bennett a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Bernice L. Robinson-Bennett is classified as an Distinguished expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Bernice L. Robinson-Bennett specialize in?

While Dr. Bernice L. Robinson-Bennett is a Oncology, they have specific expertise in Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Endometrial Stromal Sarcoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Bernice L. Robinson-Bennett participate in research or clinical trials?

Yes. Dr. Bernice L. Robinson-Bennett has published 3 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Bernice L. Robinson-Bennett's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Bernice L. Robinson-Bennett accept my insurance?

Dr. Bernice L. Robinson-Bennett accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 484-628-8905 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robinson-Bennett's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile